Background: To date, sex difference in outcomes among patients with intracranial atherosclerosis (ICAS) has rarely been discussed in China as well as in the world. This study aimed to estimate the sex difference in outcomes among patients with ICAS in Chinese cerebral ischemia patients. Methods: We analyzed 1,335 men and women with ICAS who were enrolled in the Chinese Intracranial Atherosclerosis study. They were followed-up for ischemic stroke recurrence, any cause of death, cerebral vascular events (including transient ischemic attack, ischemic and hemorrhagic stroke), combined end points (including cerebral vascular events, angina or myocardial infarction, pulmonary embolism, peripheral vascular events), and unfavorable outcome (modified Rankin scale score of 3-6) at 1 year. Results: During the follow-up period, 59 (13.44%) combined end points were documented in women and 107 (11.94%) in men. Of the combined end points, 47 were recurrent ischemic stroke events (14 in women and 33 in men), and 51 other causes of deaths (24 in women and 27 in men). There were 349 unfavorable end points (117 in women and 232 in men). The cumulative probability of death was higher in women, but after adjusting for age, diabetes mellitus, hypertension, family history of stroke, current smoker, heavy drinking, hyperhomocysteinemia, and heart disease, there was no significant difference. There was also a lack of difference in 1-year ischemic stroke recurrence, cerebral vascular events, combined end points, and unfavorable outcome between women and men at 1 year. Conclusions: These results suggest no sex difference in outcome among patients with ICAS in Chinese cerebral ischemia patients.

Keywords:
Cerebrovascular disease, Sex difference, Outcome, Intracranial atherosclerosis
1.
Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, Giroud M, Rudd A, Ghetti A, Inzitari D; European BIOMED Study of Stroke Care Group: Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke 2003;34:1114-1119.
2.
Bhattacharjee M, Ahmed S, Rahman KM, Uddin MJ, Dey SK, Israil A, Mondal G, Miah AH, Roy GC: Sex differentiation and risk factor evaluation in stroke patients. Mymensingh Med J 2011;20:371-376.
3.
Arboix A, Oliveres M, Garcia-Eroles L, Maragall C, Massons J, Targa C: Acute cerebrovascular disease in women. Eur Neurol 2001;45:199-205.
4.
Labiche LA, Chan W, Saldin KR, Morgenstern LB: Sex and acute stroke presentation. Ann Emerg Med 2002;40:453-460.
5.
Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L: Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915-926.
6.
Appelros P, Stegmayr B, Terént A: Sex differences in stroke epidemiology: a systematic review. Stroke 2009;40:1082-1090.
7.
Wyller TB, Sødring KM, Sveen U, Ljunggren AE, Bautz-Holter E: Are there gender differences in functional outcome after stroke? Clin Rehabil 1997;11:171-179.
8.
Gray LJ, Sprigg N, Bath PM, Boysen G, De Deyn PP, Leys D, O'Neill D, Ringelstein EB; TAIST Investigators: Sex differences in quality of life in stroke survivors: data from the tinzaparin in acute ischaemic stroke trial (TAIST). Stroke 2007;38:2960-2964.
9.
Lai SM, Duncan PW, Dew P, Keighley J: Sex differences in stroke recovery. Prev Chronic Dis 2005;2:A13.
10.
Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M: Stroke incidence, case fatality, and mortality in the WHO MONICA project. World health organization monitoring trends and determinants in cardiovascular disease. Stroke 1995;26:361-367.
11.
Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ: Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 2007;6:456-464.
12.
Cheng XM, Ziegler DK, Lai YH, Li SC, Jiang GX, Du XL, Wang WZ, Wu SP, Bao SG, Bao QJ: Stroke in China, 1986 through 1990. Stroke 1995;26:1990-1994.
13.
Thorvaldsen P, Kuulasmaa K, Rajakangas AM, Rastenyte D, Sarti C, Wilhelmsen L: Stroke trends in the WHO MONICA project. Stroke 1997;28:500-506.
14.
Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, Wang Y, Zou X, Leung TW, Cai Y, Bai Q, Wu Y, Wang C, Pan X, Luo B, Wong KS; CICAS Study Group: Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese intracranial atherosclerosis (CICAS) study. Stroke 2014;45:663-669.
15.
Williams JE, Chimowitz MI, Cotsonis GA, Lynn MJ, Waddy SP; WASID Investigators: Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis. Stroke 2007;38:2055-2062.
16.
Wong KS, Li H: Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke 2003;34:2361-2366.
17.
Smith WS, Lev MH, English JD, Camargo EC, Chou M, Johnston SC, Gonzalez G, Schaefer PW, Dillon WP, Koroshetz WJ, Furie KL: Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. Stroke 2009;40:3834-3840.
18.
Poisson SN, Nguyen-Huynh MN, Johnston SC, Furie KL, Lev MH, Smith WS: Intracranial large vessel occlusion as a predictor of decline in functional status after transient ischemic attack. Stroke 2011;42:44-47.
19.
Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators: Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology 2003;22:106-117.
20.
Rundek T: Do women have worse outcome after stroke caused by intracranial arterial stenosis? Stroke 2007;38:2025-2027.
21.
Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K; Riks-Stroke Collaboration: Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 2003;34:1970-1975.
22.
Meseguer E, Mazighi M, Labreuche J, Arnaiz C, Cabrejo L, Slaoui T, Guidoux C, Olivot JM, Abboud H, Lapergue B, Raphaeli G, Klein IF, Lavallée PC, Amarenco P: Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: a clinical registry study and systematic review. Stroke 2009;40:2104-2110.
23.
Hill MD, Kent DM, Hinchey J, Rowley H, Buchan AM, Wechsler LR, Higashida RT, Fischbein NJ, Dillon WP, Gent M, Firszt CM, Schulz GA, Furlan AJ; PROACT-2 Investigators: Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke 2006;37:2322-2325.
24.
Reeves M, Bhatt A, Jajou P, Brown M, Lisabeth L: Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis. Stroke 2009;40:1743-1749.
25.
Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH; Get with the Guidelines-Stroke Steering Committee & Investigators: Quality of care in women with ischemic stroke in the GWTG program. Stroke 2009;40:1127-1133.
26.
Cavallari LH, Helgason CM, Brace LD, Viana MA, Nutescu EA: Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother 2006;40:812-817.
27.
Boden-Albala B, Litwak E, Elkind MS, Rundek T, Sacco RL: Social isolation and outcomes post stroke. Neurology 2005;64:1888-1892.
28.
Siegel C, Li J, Liu F, Benashski SE, McCullough LD: miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. Proc Natl Acad Sci U S A 2011;108:11662-11667.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.